ECVT & ECCT

Group B breast cancers typically react well to ECCT treatment, causing tumors up to 3-5 cm in size to go away completely and revert to normal tissue. The way that various tumor types react to electric field treatment with ECCT depends on how those cancers are classified based on their electrical index. Tools for measuring the electrical activity index, which characterizes the subtypes, are provided by ECVT.

Different varieties of breast tumors react differently to the treatment. such as shrinkage (Groups C1 and C2), solid-turn-to-cystic (Group A), and solid-turn-to-necrotic (Group D). Together with a team from CTech Labs of Indonesia, Akiyama from the Clinical Oncology Department at McGill University in Canada published the study in the Journal of the World Academy of Anti-Aging and Regenerative Medicine 2024; 6: 20–33.

Link:https://waarm.or.jp/wp-content/uploads/2025/02/20-33_ECCT-Physical-Therapy-for-Cancer_Shinichiro-Akiyama.pdf

Ikuti pemaparan terkait sejarah awal pengembangan teknologi ECVT yang pertama dipakai oleh NASA dan Departemen Energi Amerika Serikat hingga pengembangan terbaru teknologi turunannya yaitu alat terapi kanker ECCT di podcast Bicara Iptek oleh inventornya langsung Dr. Warsito Purwo Taruno.

Link di komen.

Perkembangan Teknologi Terapi Kanker di Indonesia - Dr. Warsito Purwo Taruno | Bicara Iptek #7 Membahas mengenai teknologi tomografi dengan pengembangannya dalam terapi kanker di Indonesia.Kontak tim Dr. Warsito untuk terapi Kanker bisa melalui:https:/...

CASE: A 40-year-old woman was diagnosed with a bone tumor in her right thigh. It recurred two months after surgery and radiation.

A PET-CT scan two months after surgery showed recurrence in the post-surgery and radiation area, along with metastasis to the lungs and lymph nodes surrounding the trachea, bronchi, and supraclavicular and neck lymphnodes. A biopsy revealed a poorly differentiated adenocarcinoma with ALK-positive mutation detected. The mass in her right thigh likely originated from her lung.

This case is considered end-stage. Poorly differentiated adenocarcinoma is a highly aggressive type that generally has a poorer prognosis than moderately or well-differentiated types. In general, the prognosis for end-stage lung cancer is relatively poor, with survival rate only around 6-12 months even with treatment.

However, this type has a better response to ECCT than less aggressive types. Poorly differentiated adenocarcinomas have higher electrical polarity than moderately or well-differentiated types, resulting in a better response to ECCT. Cells die more quickly with exposure of the electric field, dead cells are discharged more easily due to their softer nature. Probability to achieve remission is higher regardless of staging. Metastasis is relatively less issue with ECCT as long as the spread remains in the form of small nodules, so the level of damage to the invaded tissue is not too severe.

In this case, the patient also received targeted drugs in combination with the usage of ECCT device. ECCT effectively kills malignant cells, while the targeted drugs suppress the growth factor of the cells. If both work well, remission is highly possible, even in cases with extensive spread.

The success rate of this combination therapy is still influenced by how quickly the dead cells are discharged to outside of the body through the body's natural mechanisms as well as the extent of tissue/organ damage that has been invaded by malignant cells. For cases with widespread metastasis in the form of small nodules, this is generally the case.

A CT scan after 3 months of use of the device showed the main mass in the lung had shrunk from 3.8x2.3 cm to 1.8x1.3 cm. Another PET-CT scan after 6 months of usage of the device showed the malignant mass had been relatively cleared. The patient's general condition is relatively normal.

The latest advancement in ECCT shows that well-differentiated adenocarcinoma with a wild-type EGFR mutation dies and changes into a mass with high cholesterol content within 30 minutes of being subjected to an electric field. It is also possible for a 5-cm-diameter lump of recurrent tumor to shrink to normal tissue in two months.

In 6 months, ECCT removes the primary tumor of high-grade adenocarcinoma of the prostate, as well as all metastatic lymph nodes and bone lesions, with the exception of the area of the face and neck that is uncovered by the device, as seen in this case.

CASE: A 72-year-old French man was diagnosed with prostate cancer with a Gleason score of 9/10 in September 2023. The PET scan results revealed that cancer cells had penetrated the entire prostate gland, spread to lymph nodes in the pelvis and surrounding the aortic blood veins, and reached locations in the hip bones. It was revealed that his disease was already at stage 4.

He then decided to take hormone-suppressing medication while receiving ECT (Electric Cancer Therapy) in Germany and taking the GcMaf immunotherapy supplement from Japan. After about a year of medication, a PET scan revealed that the spread to the lymph nodes had spread to the entire chest and neck area, and the bone spread had reached places up to the skull; meanwhile, the mass in the prostate had completely filled the prostate.

He first used the ECCT device in December 2024. He had no severe concerns while using the ECCT devices. Because the cancer spreads in the form of small points, despite its widespread nature, and the cell type is vulnerable (easily destroyed by an electric field) and the dead cells are relatively easy to leave from the body by excretion such as sweating, urine, and f***s. Even if the cancer has spread far, it can still be completely treated as long as the extended area is well covered by the device.

The PET scan outcomes after 6 months of implementing ECCT revealed that the cancer mass was mostly clean in the prostate and all areas where it spread, including lymph nodes from the pelvis to the chest and all bones, with the exception of the face and neck, which he refused to cover from the start. After reviewing the PET scan results, he agreed to use the new device, which covers his full body, including the face and the neck area. His overall condition is quite normal.